Author: Ian Mason

New data supporting the safety and long-term efficacy of Eisai’s Zonegran when used as adjunctive therapy in adolescents and children aged six years and above, with partial (focal) epilepsy have been presented at the European Paediatric Neurology Society meeting, held this week in Brussels.

A tiny pain-free jab every two weeks could be the future of cholesterol-lowering for high-risk patients, according to clinical researchers gathered in Amsterdam for the European Society of Cardiology congress.

Investigators have presented full results from a late-stage study which sheds more light on Sanofi’s decision to halt development of its injectable factor Xa inhibitor otamixaban.

Daiichi Sankyo’s once-daily oral factor Xa inhibitor edoxaban is as effective as warfarin with a better safety profile when used for preventing recurrence of acute venous thromboembolism, according to results from the Phase III Hokusai-VTE trial presented at the European Society of Cardiology congress in Amsterdam.

Sanofi Pasteur is poised to produce the first validation batches of their dengue vaccine at the company’s state-of-the-art production centre near Lyon, France.